{"ticker": {"uuid": "16348ae7-bb53-4a56-889a-1cfd8a917102", "symbol": "IMNN", "name": "Imunon Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR\u2019s David Bautz, PhD", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-160200306.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-09T16:02:00+00:00", "published_display": "09 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Susan Eylward Sells Shares of Imunon Inc (IMNN)", "summary": "Susan Eylward, General Counsel and Corporate Secretary at Imunon Inc's subsidiary, sold 920 shares of IMNN on July 6, 2026. This transaction brings her total ownership down to 2,896 shares. Over the past year, there have been no insider buys and two insider sells at Imunon Inc, w", "url": "https://www.gurufocus.com/news/8948375/insider-sell-susan-eylward-sells-shares-of-imunon-inc-imnn", "source_name": "GuruFocus", "published_at": "2026-07-07T22:39:11", "published_display": "07 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon general counsel Susan Eylward sells $1,729 in company stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOenVlaHFqN2dhNGN6WGhweEJremR0R2pOMXd2bFEyOE5UTHdTX1JHcVFsLUpMMTRTcms2QlZmdF94R2tUMEwwdHR3T3JJeGlxeUNxRkNCenQyb0lTVnFzTk9jUFhXVGJLZmtSRGVFRFZjS0ktdkVvRVhmd2k2YVRLZjdwODFhS3FnVmNpbFBnam1kNHlvWEU1OXBGRG95el9DNDY3eXN1QWtTdWtjV0lQc09DSnZjWmY2WFNLQ2VJa2VVR28?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T21:38:41+00:00", "published_display": "07 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CFO Joshua Blacher files initial insider Form 3 ownership report", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUWNuVW9IcVZ3c2FtMmxPQ09iaFQxR1hDTjZRMFl3a3lBOElXd2s4ZWtBQjB6ZnVmZVAwSFA2allGeVN3MXlmVUJ0ZkxiNk1GQjUxclFybkQ0MWtKX3dxeUxoMlU2NnBteXllTXdDZXk3THI0VDRBVnlUUzJRUXJYMHQ4V2RBWGI4Rml0a0VrUGFSMHNCRzJHZnJlVFY4c0hCaGh0U2tKaGFyVkEwa1FVSVFVMzB5bHRLc1RBSUhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T21:01:17+00:00", "published_display": "07 Jul 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Imunon Inc For: 7 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Imunon Inc. on July 7, 2026. Form 4s typically report changes in beneficial ownership of company stock by insiders. The article notes Imunon Inc. (IMNN) is up 7.69%.", "url": "https://ng.investing.com/news/stock-market-news/form-4-imunon-inc-for-7-july-93CH-2589886", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T21:40:16", "published_display": "07 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon general counsel Susan Eylward sells $1,729 in company stock", "summary": "Imunon's General Counsel, Susan Eylward, recently sold 920 shares of company stock for $1,729. This transaction followed her acquisition of the same number of shares, granted in lieu of salary, valued at $1,757. The stock is currently trading near its 52-week low, and company ana", "url": "https://www.investing.com/news/insider-trading-news/imunon-general-counsel-susan-eylward-sells-1729-in-company-stock-93CH-4780260", "source_name": "Investing.com", "published_at": "2026-07-07T21:39:10", "published_display": "07 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) Executive Chairman receives 4,410-share stock grant as salary", "summary": "Imunon, Inc. Executive Chairman Michael H. Tardugno received a grant of 4,410 shares of common stock at $1.91 per share, issued in lieu of cash for his base salary. This transaction increased his direct ownership to 64,396 shares, with an additional 4,622 shares held indirectly t", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-76895a530381.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:16", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CMO granted stock in lieu of part of salary", "summary": "Imunon's Chief Medical Officer, Douglas Vincent Faller, received a grant of 1,308 shares of Common Stock on July 2, 2026, at $1.91 per share. This stock grant was provided in lieu of a portion of his base salary, making it a non-market compensation transaction. Following this tra", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-1206984b52eb.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:16", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) General Counsel reports stock grant and 920-share sale", "summary": "Imunon, Inc.'s General Counsel, Susan Eylward, reported receiving a stock grant of 920 shares at $1.91 each on July 2, 2026, as part of her base salary. She subsequently sold 920 shares in an open-market transaction at $1.88 each on July 6, 2026. After these transactions, Eylward", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-5e7915b69f19.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:39:11", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CEO Stacy Lindborg receives stock grant instead of cash salary", "summary": "Imunon, Inc.'s President and CEO, Stacy Lindborg, received a grant of 2,534 shares of common stock at $1.91 per share as part of her compensation, in lieu of a portion of her base salary. Following this transaction, Lindborg directly holds 76,722 shares and indirectly holds 778 s", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-0a22a0212be9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:39:10", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon 1Q Loss/Shr 84c >IMNN", "summary": "Imunon (IMNN) reported a first-quarter loss per share of 84 cents. This financial update provides key information regarding the company's recent performance.", "url": "https://www.moomoo.com/news/post/69834232/imunon-1q-loss-shr-84c-imnn?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T01:13:57", "published_display": "07 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 24, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon Names Josh Blacher Interim Chief Financial Officer", "summary": "Imunon has appointed Josh Blacher as interim Chief Financial Officer, effective July 1, 2026, following the retirement of Jeffrey Church. Blacher, a finance executive from Danforth Health, Inc., will serve as the principal financial and accounting officer. The company's stock, IM", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMNN-Q/pressreleases/3086778/imunon-names-josh-blacher-interim-chief-financial-officer/", "source_name": "The Globe and Mail", "published_at": "2026-07-04T05:09:24", "published_display": "04 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNN - Imunon Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Imunon Inc. (IMNN), alongside a comprehensive financial overview. It details key financial metrics, stock performance data, and insider/institutional ownership figures for the company.", "url": "https://finviz.com/stock?t=IMNN&ta=1&p=d&ty=lf&b=2&page=20", "source_name": "Finviz", "published_at": "2026-07-03T15:09:08", "published_display": "03 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (NASDAQ: IMNN) appoints Josh Blacher as interim CFO", "summary": "Imunon, Inc. (NASDAQ: IMNN) has appointed Josh Blacher as its new interim Chief Financial Officer, effective July 1, 2026. This appointment follows the retirement of the previous interim CFO, Jeffrey Church, who will remain with the company as a consultant. Blacher will serve thr", "url": "https://www.stocktitan.net/sec-filings/IMNN/8-k-imunon-inc-reports-material-event-1631fe4eb57f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:24", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon CFO Jeffrey Church to Retire; Josh Blacher Named Interim CFO", "summary": "Imunon has announced that its interim Chief Financial Officer, Jeffrey Church, will retire effective July 1, 2026. Josh Blacher has been named the interim CFO, taking over on the same date. Church will continue as a consultant for Imunon under an amended Consulting Agreement.", "url": "https://www.tradingview.com/news/tradingview:2959934a6e672:0-imunon-cfo-jeffrey-church-to-retire-josh-blacher-named-interim-cfo/", "source_name": "TradingView", "published_at": "2026-06-30T20:39:24", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Imunon Inc For: 29 June By Investing.com", "summary": "This article from Investing.com announces the Form 4 filing for Imunon Inc. on June 29th. It is a brief, factual notification regarding a regulatory filing for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-imunon-inc-for-29-june-93CH-2578824", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T14:12:00", "published_display": "30 Jun 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CEO awarded 67,150 shares instead of cash bonus", "summary": "Imunon, Inc. President and CEO Stacy Lindborg received a stock-based compensation grant of 67,150 shares at $1.72 per share, in lieu of 50% of her 2025 annual cash bonus. Following this transaction, Lindborg directly holds 74,188 shares and indirectly holds 778 shares through a 4", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-5a1b356e44d8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:14:21", "published_display": "30 Jun 2026 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) counsel gets stock bonus, then sells 11,800 shares", "summary": "Imunon's General Counsel, Susan Eylward, received 14,696 shares of common stock at $1.72 per share as part of her 2025 annual bonus. Shortly after, she sold 11,800 shares in an open-market transaction at a weighted average price of $1.752 per share, retaining 2,896 shares. This t", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-a345e0b9ec85.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:14:20", "published_display": "30 Jun 2026 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Susan Eylward Sells 11,800 Shares of Imunon Inc (I", "summary": "Susan Eylward, General Counsel and Corporate Secretary at a subsidiary of Imunon Inc, sold 11,800 shares of Imunon Inc (IMNN) on June 29, 2026. After this transaction, Eylward now holds 2,896 shares. Imunon Inc, a biotechnology company, has seen no insider buys but one insider se", "url": "https://www.gurufocus.com/news/8937104/insider-sell-susan-eylward-sells-11800-shares-of-imunon-inc-imnn", "source_name": "GuruFocus", "published_at": "2026-06-29T23:14:20", "published_display": "29 Jun 2026 23:14", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) chair takes half of 2025 cash bonus in stock grant", "summary": "Imunon's Executive Chairman, Michael H. Tardugno, received 42,519 shares of common stock valued at $1.72 per share, in lieu of 50% of his 2025 annual cash bonus. This stock grant increases his direct holdings to 59,986 shares, plus an additional 4,622 shares held indirectly throu", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-05f9fbcc7fb1.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:14:21", "published_display": "29 Jun 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) Chief Medical Officer granted 21,896 shares in lieu of 2025 cash bonus", "summary": "Imunon, Inc.'s Chief Medical Officer, Douglas Vincent Faller, was granted 21,896 shares of common stock at $1.72 per share. This stock grant serves as 50% of his 2025 annual cash bonus, rather than a cash payment. Following this transaction, Faller directly owns 21,896 shares of ", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-29bdd6c2be7c.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:14:21", "published_display": "29 Jun 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Imunon, Inc. \u2013 NASDAQ:IMNN", "summary": "The article presents financial data for Imunon, Inc. (NASDAQ: IMNN), specifically focusing on its enterprise value to EBITDA forward metric. The content itself seems to be a display from a financial data platform, providing a snapshot of the company's financial overview. It does ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:09:21", "published_display": "29 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Imunon, Inc. \u2013 DUS:CBO0", "summary": "The article provides a financial data point for Imunon, Inc. (DUS:CBO0) on its price to earnings forward, indicating \"No trades\" at market close. The content is primarily a data page from TradingView, displaying financial overview information for the company.", "url": "https://www.tradingview.com/symbols/DUS-CBO0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:19", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Imunon, Inc. \u2013 NASDAQ:IMNN", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" for Imunon, Inc. (NASDAQ: IMNN). It indicates that the market was closed with no trades at the time of publication. The content primarily shows the financial metric \"Period Value Change Change %\" for the compa", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:40:47", "published_display": "28 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Imunon, Inc. \u2013 NASDAQ:IMNN", "summary": "This article provides a financial data point for Imunon, Inc. (NASDAQ: IMNN), specifically its \"Price to book forward\" metric. The content indicates that for this particular period, the value is not available, showing \"No trades.\" It appears to be a stub or an entry from a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:22", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. Actuals & Estimates (FWB:CBO0)", "summary": "This article provides key financial data and analyst insights for Imunon, Inc. (FWB:CBO0), including its stock ticker, price forecasts ranging from 8.61 EUR to 21.53 EUR, and historical price movements. It details recent earnings, revenue, and net income figures, noting that the ", "url": "https://www.tradingview.com/symbols/FWB-CBO0/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T16:10:52", "published_display": "27 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. Actuals & Estimates (DUS:CBO0)", "summary": "This article provides an overview of Imunon, Inc. (DUS: CBO0) stock, including financial actuals and estimates, analyst forecasts with price targets, and historical price data. It details recent earnings and revenue figures, upcoming earnings release dates, and confirms the compa", "url": "https://www.tradingview.com/symbols/DUS-CBO0/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T05:39:48", "published_display": "27 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. (IMNN) Presents at Life Sciences Virtual Investor Forum - Slideshow (NASDAQ:IMNN) 2026-06-26", "summary": "Imunon, Inc. (IMNN) presented a slideshow at the Life Sciences Virtual Investor Forum. The article highlights that SA Transcripts published the slide deck and is responsible for developing all transcript-related projects for Seeking Alpha. This event provides investors with insig", "url": "https://seekingalpha.com/article/4917926-imunon-inc-imnn-presents-at-life-sciences-virtual-investor-forum-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-26T04:10:21", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A41CNR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast for Imunon, Inc. (A41CNR) stock, including price targets, analyst ratings, and historical performance data. It highlights that analysts have a max estimate of 21.53 EUR and a min estimate of 8.61 EUR for the stock, despite recent declines", "url": "https://www.tradingview.com/symbols/LSX-A41CNR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:38:50", "published_display": "25 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. Actuals & Estimates (NASDAQ:IMNN)", "summary": "This article provides an overview of Imunon, Inc. (NASDAQ:IMNN) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, such as earnings, revenue, net income, and upcoming earnings release d", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:38:50", "published_display": "25 Jun 2026 23:38", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Imunon, Inc. (IMNN) stock, based on analyst opinions. It details the company's current stock performance, historical highs and lows, market capitalization, earnings reports, and technical analysis indicators. The article also ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:21", "published_display": "25 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imunon-apos-phase-3-ovarian-124810813.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:48:10+00:00", "published_display": "23 Jun 2026 12:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imunon-announces-data-monitoring-committee-120000811.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:00:00+00:00", "published_display": "23 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) executive chair granted 4,629 shares in lieu of cash pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQndFUTZRSDFUSkxVSW5ueUM2ZGhKdC1FTG5mY09fNkJZSkJhWWlMMFlDZlNLWTFPVU5vaS1RZUhOaTM4aDN1NWFlNjdqeWNiV3R3T0U2OEJrSjNqbW1ZMWllVC1TRmt6ZWlxSFFlYWxTMF9BU0FZYnNVZENBbW5DODJzWUszS3RnVjJXaEZKLUl1VlFrYUxKTnJWVXc1SlBHdXdXS1VONA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON\u2019s Phase 3 OVATION 3 Trial in Advanced Ovarian Cancer Recommended to Continue by Independent Data Monitoring Committee", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPWmVuUS1aa1BtTXM1NndtSzhjTWNKLU1qN0prSERvVWZxU3RZTkl4Z1NXRHhpLU1OVkh5Q1NEVmMyeEFGWmc5WTJFU2F3T1ZUUHp1bktveGJ4MjRtOUN6dG1iXzd3T0NxazJLWm83YW9xOXRzMVh2UUMwWTNZZE5ZT2lxTzhmMG4wdWZ5cnVVN21zRGVjcHhhSV9aNXlnVUhUXzY4ZElvNjczVFV6OXZrT0FybzZ1UHV1M3BkdldBWF9kMHQ3alBoeDhDNDVNaXRsWmNkWU82Nm50QmZLQmVCWlo2dGpNbXJSV2dEYnNwQW5ISkpRdkJ6TA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON ovarian cancer trial stays on track after safety review", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPb1ZqLV9FUWFrRFBLXzJQSzV5RXk0N1c1QnRSbnNUWjRjenBmQkd3UXlhTEF4RF9wTWNVUTRhajJmeDBockd2eDdTN0xSZ1h3NVFlN3RUcS1fbDVrMGdrR05wUnhIZ3pfUHZpbTJKbWdMeXJJT3NQYkEtTjZSSkVXSk1Yb0RMV3pBdy1YWWZ1b0doZzVjSnpnNndtT3JaanlpeU9MTHE2enZlc0x3MUdTcnp0bjk4WjF0N0M0YVlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON to Present at the Life Sciences Investor Forum on June 25th", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imunon-present-life-sciences-investor-201500924.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:15:00+00:00", "published_display": "22 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON CEO to take live questions June 25 at investor forum", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWVlDTDlJeWhFN3B1YkNiVFlfbmViM2xtZHcwcHFHZHZ1MDh6OVFSWWc1NTBjS29VbzhmeTBNUmtDTmctTmttVE0wb091OHhCcUZlOHQ5X0k5TzFjbFFxdm96cnlBOG9xSWhVTUNIQXIzWU9zV0pvcnlKVWc3U1RQUW5lZXM1TmpDaklGWmlFR0FYRHJxSGxTNHZFT3B3aWg1YnVmOWh1dUszVjVqZTFzWWxFbGFyQ1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)", "summary": "", "url": "https://finance.yahoo.com/m/0d6c8b3c-3e89-3260-8f6d-9a1b035ee5f7/imunon-secures-%2410-million.html", "source_name": "InvestorsHub", "published_at": "2026-06-04T14:32:14+00:00", "published_display": "04 Jun 2026 14:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON Announces Up to $10 Million Cash Financing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/imunon-announces-10-million-cash-120000292.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON raises $10M after ovarian cancer drug shows 14.7-month gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQWWNXQzJtZEV4bUtBWXlqMHM3bWNHSEMzX1lfdnlYVVR2MU41ajliRWYxQ1J1d25GU2ZYQjJFSF92aF8zX25nVmdkT3JqZVlwaVU0d1ZqOXlGWHB6ck43bndLMEtlZUVSX0hvSDhfWkwyVy11OFF5UHlKMF9RUGpMYUthcTNBdVg1OUpTYlBrR192eUs4ZG50Zg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon Secures $10 Million Financing From Streeterville Capital; Issues Preferred Stock and Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNYkh3S2lXS1M0MVhicXJmb3FJLXRydkhrUGMyTGJEcjR5M25uRmozLUdCQjk0cENYRFBLeWtNdWxTM2trNUhXeUtySmpldlRpUDY5LUtOeTg3aTFmYmgwQTM1a0V0cVprdEdOdUJjWUt3UXE0eGlyM0MzaW1vc0VjbDdvUUQ1NGdqMk44eHo2alo2UEl5NmsxdHQyTUtCbW9lSXNEc0ZtRDZDbV9ZSERZMXoyNzZyQXg1WUlzZk1Oa2lmcmpxZWVLbGxrTG5SNDJZOHNVcFp2ZFAtclNRWmMzaVduZmNpYXVOWkd6bDRn?oc=5", "source_name": "TradingView", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon IMNN Q4 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/77750952-a2fb-3f6a-b5a6-934811196618/imunon-imnn-q4-2025-earnings.html", "source_name": "Motley Fool", "published_at": "2026-06-01T15:47:00+00:00", "published_display": "01 Jun 2026 15:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "May 12 webcast to cover IMUNON's Q1 results, Phase 3 ovarian cancer update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZnprVjhXTjFrbEFSbWZOcndKd0ZMX2xfN3RYTlA5bVNXODVuek11U3Vob1phRlVPb3N3cFY1OWdLdGVubUY4LWF0aG1raWpOTGlqMTZOalBXSVgySDFaVXJhTVJXaE5uZXhzOFdZZ2dqSWFQR1JRTllTdGNKQlFmMWFIRzNONjh3bnZkdkc1YTVpMGNsX1ZGOUE5bklvaGJRa19jcF9EZkp2X3JWbkN0SjVzRzNzUERfaTlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IMUNON Reports 2025 Financial Results and Provides Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxPX0NuT0hFdXRLdS1HcGpTNFVldWlGSDVHUnp1a1NnRkdqUWlQM1pXUlNLYWY4VHExSHhoS2dkcGxtYnhBVFlBR1RtTG9UWGpKV0ZDbXprRHVxZktrM3N1S2R4SnFXc21YYkNWbGdTY3JLODB3eW0xQS1wVTJYRGpUaXhGc3Jxd2ZORTVOeTc5MnBlMjdyWFBpNzdRLWV4SEZ6NE1LQ1JNUnQ5MDBhZ3RJckRta3lhMjdabnBrZXlDTnZKcTEtc0RKWjZIdlFwM3JDa2xwQTdqdG02NV9zTk9VeThvUGdxWWNKQ3pDVTBlZGtTbG04dzdpUXkxZnF3czQzVVJUMno1NWE2SkRBUUc2NGwxY3JyV1FEQWw3dHdzVlNwZFZIWmc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IMUNON Reports Updated Phase 2 Data Showing Continued", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxPZEoyRG90cWxrNWw3QWJrYzBBR3hfc21JWU1QZUhqZ1BDRjlKVC1ic2luOEVrNTRQQzdEWF9LZ1JHVC1GZThQSTloUHYwZjhBXzB4NHczdWExbk53NXNOS1IwendMZlZoclFYNWh1TUZLdXdGVElHbDJIekM4a01mcXQ5NmVSdENEay1oMF9COTM5UmgzMldlUHlRM2l2eXJBT2pYTU0yblBhS0ZZR2hsZ2pOaThmaGNPclRhZ1prb1c5RjZzNUNrUDBmcnlXalctNmFuaEJFS1ZpMEt6V0gwUkl3eEpZVjBfUmtIVzNFLUZLZGk0bmpqMXczSlR2Ylp1bHpBVWpGdGV3bF9sdnBSYjFwOFFLOVYydnhleXcybkZEQUdBYWNldGR6bkZBTWRoTVpEUDJ0RFcyeGtvRU9vbjZDQjBtbGFxbGhOcTJiMTM1dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNSGxKSGtPZ1dmSV96MFdVbEc5U183M1NwSmhjcXZkM3BMNFYwUTBUTjVGc0w2ZkNhdDlDS2J6SzN2T1FrVXd2UEV3N0EtanBfSkY5VkI1ZlRxY1luaVhJYURMblN1QWh5SHF0WnNSY0NRU1kxWEs3S1ZlNEF2OUNvWl84eHljSUZXa3JaRkZKeTNwUWZIWVVjS1JLU2M4QWNrNFdkTnBzYWstWE1ubHlMSW9Xc3hxeHh5cEw0azZiZXZBbGt5amZZTWZqNWNadDFtczFqZFNfR0Fuc2Mzdml1QWlIc3lKcW1lcHozZ0V0dFgxcVotWW5XNVYxcnVYY28?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBGVnRGYUhsYXhWM2kyb094eTUyX0c5eGZBLVY5ajF6M0NJMERFbkFCVDlFU2diWkdSUzBNS2JNLWhicVlTOTNHaGlQa2EzTVhOQ2JKTk9nemJZZw?oc=5", "source_name": "MarketBeat", "published_at": "2022-09-24T13:23:29+00:00", "published_display": "24 Sep 2022 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR\u2019s David Bautz, PhD", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-160200306.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-09T16:02:00+00:00", "published_display": "09 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Susan Eylward Sells Shares of Imunon Inc (IMNN)", "summary": "Susan Eylward, General Counsel and Corporate Secretary at Imunon Inc's subsidiary, sold 920 shares of IMNN on July 6, 2026. This transaction brings her total ownership down to 2,896 shares. Over the past year, there have been no insider buys and two insider sells at Imunon Inc, w", "url": "https://www.gurufocus.com/news/8948375/insider-sell-susan-eylward-sells-shares-of-imunon-inc-imnn", "source_name": "GuruFocus", "published_at": "2026-07-07T22:39:11", "published_display": "07 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon general counsel Susan Eylward sells $1,729 in company stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOenVlaHFqN2dhNGN6WGhweEJremR0R2pOMXd2bFEyOE5UTHdTX1JHcVFsLUpMMTRTcms2QlZmdF94R2tUMEwwdHR3T3JJeGlxeUNxRkNCenQyb0lTVnFzTk9jUFhXVGJLZmtSRGVFRFZjS0ktdkVvRVhmd2k2YVRLZjdwODFhS3FnVmNpbFBnam1kNHlvWEU1OXBGRG95el9DNDY3eXN1QWtTdWtjV0lQc09DSnZjWmY2WFNLQ2VJa2VVR28?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T21:38:41+00:00", "published_display": "07 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CFO Joshua Blacher files initial insider Form 3 ownership report", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUWNuVW9IcVZ3c2FtMmxPQ09iaFQxR1hDTjZRMFl3a3lBOElXd2s4ZWtBQjB6ZnVmZVAwSFA2allGeVN3MXlmVUJ0ZkxiNk1GQjUxclFybkQ0MWtKX3dxeUxoMlU2NnBteXllTXdDZXk3THI0VDRBVnlUUzJRUXJYMHQ4V2RBWGI4Rml0a0VrUGFSMHNCRzJHZnJlVFY4c0hCaGh0U2tKaGFyVkEwa1FVSVFVMzB5bHRLc1RBSUhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T21:01:17+00:00", "published_display": "07 Jul 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Imunon Inc For: 7 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Imunon Inc. on July 7, 2026. Form 4s typically report changes in beneficial ownership of company stock by insiders. The article notes Imunon Inc. (IMNN) is up 7.69%.", "url": "https://ng.investing.com/news/stock-market-news/form-4-imunon-inc-for-7-july-93CH-2589886", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T21:40:16", "published_display": "07 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon general counsel Susan Eylward sells $1,729 in company stock", "summary": "Imunon's General Counsel, Susan Eylward, recently sold 920 shares of company stock for $1,729. This transaction followed her acquisition of the same number of shares, granted in lieu of salary, valued at $1,757. The stock is currently trading near its 52-week low, and company ana", "url": "https://www.investing.com/news/insider-trading-news/imunon-general-counsel-susan-eylward-sells-1729-in-company-stock-93CH-4780260", "source_name": "Investing.com", "published_at": "2026-07-07T21:39:10", "published_display": "07 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) Executive Chairman receives 4,410-share stock grant as salary", "summary": "Imunon, Inc. Executive Chairman Michael H. Tardugno received a grant of 4,410 shares of common stock at $1.91 per share, issued in lieu of cash for his base salary. This transaction increased his direct ownership to 64,396 shares, with an additional 4,622 shares held indirectly t", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-76895a530381.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:16", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CMO granted stock in lieu of part of salary", "summary": "Imunon's Chief Medical Officer, Douglas Vincent Faller, received a grant of 1,308 shares of Common Stock on July 2, 2026, at $1.91 per share. This stock grant was provided in lieu of a portion of his base salary, making it a non-market compensation transaction. Following this tra", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-1206984b52eb.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:16", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) General Counsel reports stock grant and 920-share sale", "summary": "Imunon, Inc.'s General Counsel, Susan Eylward, reported receiving a stock grant of 920 shares at $1.91 each on July 2, 2026, as part of her base salary. She subsequently sold 920 shares in an open-market transaction at $1.88 each on July 6, 2026. After these transactions, Eylward", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-5e7915b69f19.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:39:11", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CEO Stacy Lindborg receives stock grant instead of cash salary", "summary": "Imunon, Inc.'s President and CEO, Stacy Lindborg, received a grant of 2,534 shares of common stock at $1.91 per share as part of her compensation, in lieu of a portion of her base salary. Following this transaction, Lindborg directly holds 76,722 shares and indirectly holds 778 s", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-0a22a0212be9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:39:10", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon 1Q Loss/Shr 84c >IMNN", "summary": "Imunon (IMNN) reported a first-quarter loss per share of 84 cents. This financial update provides key information regarding the company's recent performance.", "url": "https://www.moomoo.com/news/post/69834232/imunon-1q-loss-shr-84c-imnn?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T01:13:57", "published_display": "07 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 24, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon Names Josh Blacher Interim Chief Financial Officer", "summary": "Imunon has appointed Josh Blacher as interim Chief Financial Officer, effective July 1, 2026, following the retirement of Jeffrey Church. Blacher, a finance executive from Danforth Health, Inc., will serve as the principal financial and accounting officer. The company's stock, IM", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMNN-Q/pressreleases/3086778/imunon-names-josh-blacher-interim-chief-financial-officer/", "source_name": "The Globe and Mail", "published_at": "2026-07-04T05:09:24", "published_display": "04 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNN - Imunon Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Imunon Inc. (IMNN), alongside a comprehensive financial overview. It details key financial metrics, stock performance data, and insider/institutional ownership figures for the company.", "url": "https://finviz.com/stock?t=IMNN&ta=1&p=d&ty=lf&b=2&page=20", "source_name": "Finviz", "published_at": "2026-07-03T15:09:08", "published_display": "03 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (NASDAQ: IMNN) appoints Josh Blacher as interim CFO", "summary": "Imunon, Inc. (NASDAQ: IMNN) has appointed Josh Blacher as its new interim Chief Financial Officer, effective July 1, 2026. This appointment follows the retirement of the previous interim CFO, Jeffrey Church, who will remain with the company as a consultant. Blacher will serve thr", "url": "https://www.stocktitan.net/sec-filings/IMNN/8-k-imunon-inc-reports-material-event-1631fe4eb57f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:24", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon CFO Jeffrey Church to Retire; Josh Blacher Named Interim CFO", "summary": "Imunon has announced that its interim Chief Financial Officer, Jeffrey Church, will retire effective July 1, 2026. Josh Blacher has been named the interim CFO, taking over on the same date. Church will continue as a consultant for Imunon under an amended Consulting Agreement.", "url": "https://www.tradingview.com/news/tradingview:2959934a6e672:0-imunon-cfo-jeffrey-church-to-retire-josh-blacher-named-interim-cfo/", "source_name": "TradingView", "published_at": "2026-06-30T20:39:24", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Imunon Inc For: 29 June By Investing.com", "summary": "This article from Investing.com announces the Form 4 filing for Imunon Inc. on June 29th. It is a brief, factual notification regarding a regulatory filing for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-imunon-inc-for-29-june-93CH-2578824", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T14:12:00", "published_display": "30 Jun 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) CEO awarded 67,150 shares instead of cash bonus", "summary": "Imunon, Inc. President and CEO Stacy Lindborg received a stock-based compensation grant of 67,150 shares at $1.72 per share, in lieu of 50% of her 2025 annual cash bonus. Following this transaction, Lindborg directly holds 74,188 shares and indirectly holds 778 shares through a 4", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-5a1b356e44d8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:14:21", "published_display": "30 Jun 2026 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) counsel gets stock bonus, then sells 11,800 shares", "summary": "Imunon's General Counsel, Susan Eylward, received 14,696 shares of common stock at $1.72 per share as part of her 2025 annual bonus. Shortly after, she sold 11,800 shares in an open-market transaction at a weighted average price of $1.752 per share, retaining 2,896 shares. This t", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-a345e0b9ec85.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:14:20", "published_display": "30 Jun 2026 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Susan Eylward Sells 11,800 Shares of Imunon Inc (I", "summary": "Susan Eylward, General Counsel and Corporate Secretary at a subsidiary of Imunon Inc, sold 11,800 shares of Imunon Inc (IMNN) on June 29, 2026. After this transaction, Eylward now holds 2,896 shares. Imunon Inc, a biotechnology company, has seen no insider buys but one insider se", "url": "https://www.gurufocus.com/news/8937104/insider-sell-susan-eylward-sells-11800-shares-of-imunon-inc-imnn", "source_name": "GuruFocus", "published_at": "2026-06-29T23:14:20", "published_display": "29 Jun 2026 23:14", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) chair takes half of 2025 cash bonus in stock grant", "summary": "Imunon's Executive Chairman, Michael H. Tardugno, received 42,519 shares of common stock valued at $1.72 per share, in lieu of 50% of his 2025 annual cash bonus. This stock grant increases his direct holdings to 59,986 shares, plus an additional 4,622 shares held indirectly throu", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-05f9fbcc7fb1.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:14:21", "published_display": "29 Jun 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) Chief Medical Officer granted 21,896 shares in lieu of 2025 cash bonus", "summary": "Imunon, Inc.'s Chief Medical Officer, Douglas Vincent Faller, was granted 21,896 shares of common stock at $1.72 per share. This stock grant serves as 50% of his 2025 annual cash bonus, rather than a cash payment. Following this transaction, Faller directly owns 21,896 shares of ", "url": "https://www.stocktitan.net/sec-filings/IMNN/form-4-imunon-inc-insider-trading-activity-29bdd6c2be7c.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:14:21", "published_display": "29 Jun 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Imunon, Inc. \u2013 NASDAQ:IMNN", "summary": "The article presents financial data for Imunon, Inc. (NASDAQ: IMNN), specifically focusing on its enterprise value to EBITDA forward metric. The content itself seems to be a display from a financial data platform, providing a snapshot of the company's financial overview. It does ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:09:21", "published_display": "29 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Imunon, Inc. \u2013 DUS:CBO0", "summary": "The article provides a financial data point for Imunon, Inc. (DUS:CBO0) on its price to earnings forward, indicating \"No trades\" at market close. The content is primarily a data page from TradingView, displaying financial overview information for the company.", "url": "https://www.tradingview.com/symbols/DUS-CBO0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:19", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Imunon, Inc. \u2013 NASDAQ:IMNN", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" for Imunon, Inc. (NASDAQ: IMNN). It indicates that the market was closed with no trades at the time of publication. The content primarily shows the financial metric \"Period Value Change Change %\" for the compa", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:40:47", "published_display": "28 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Imunon, Inc. \u2013 NASDAQ:IMNN", "summary": "This article provides a financial data point for Imunon, Inc. (NASDAQ: IMNN), specifically its \"Price to book forward\" metric. The content indicates that for this particular period, the value is not available, showing \"No trades.\" It appears to be a stub or an entry from a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:22", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. Actuals & Estimates (FWB:CBO0)", "summary": "This article provides key financial data and analyst insights for Imunon, Inc. (FWB:CBO0), including its stock ticker, price forecasts ranging from 8.61 EUR to 21.53 EUR, and historical price movements. It details recent earnings, revenue, and net income figures, noting that the ", "url": "https://www.tradingview.com/symbols/FWB-CBO0/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T16:10:52", "published_display": "27 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. Actuals & Estimates (DUS:CBO0)", "summary": "This article provides an overview of Imunon, Inc. (DUS: CBO0) stock, including financial actuals and estimates, analyst forecasts with price targets, and historical price data. It details recent earnings and revenue figures, upcoming earnings release dates, and confirms the compa", "url": "https://www.tradingview.com/symbols/DUS-CBO0/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T05:39:48", "published_display": "27 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. (IMNN) Presents at Life Sciences Virtual Investor Forum - Slideshow (NASDAQ:IMNN) 2026-06-26", "summary": "Imunon, Inc. (IMNN) presented a slideshow at the Life Sciences Virtual Investor Forum. The article highlights that SA Transcripts published the slide deck and is responsible for developing all transcript-related projects for Seeking Alpha. This event provides investors with insig", "url": "https://seekingalpha.com/article/4917926-imunon-inc-imnn-presents-at-life-sciences-virtual-investor-forum-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-26T04:10:21", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A41CNR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast for Imunon, Inc. (A41CNR) stock, including price targets, analyst ratings, and historical performance data. It highlights that analysts have a max estimate of 21.53 EUR and a min estimate of 8.61 EUR for the stock, despite recent declines", "url": "https://www.tradingview.com/symbols/LSX-A41CNR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:38:50", "published_display": "25 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon, Inc. Actuals & Estimates (NASDAQ:IMNN)", "summary": "This article provides an overview of Imunon, Inc. (NASDAQ:IMNN) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, such as earnings, revenue, net income, and upcoming earnings release d", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:38:50", "published_display": "25 Jun 2026 23:38", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Imunon, Inc. (IMNN) stock, based on analyst opinions. It details the company's current stock performance, historical highs and lows, market capitalization, earnings reports, and technical analysis indicators. The article also ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMNN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:21", "published_display": "25 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imunon-apos-phase-3-ovarian-124810813.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:48:10+00:00", "published_display": "23 Jun 2026 12:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imunon-announces-data-monitoring-committee-120000811.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:00:00+00:00", "published_display": "23 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) executive chair granted 4,629 shares in lieu of cash pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQndFUTZRSDFUSkxVSW5ueUM2ZGhKdC1FTG5mY09fNkJZSkJhWWlMMFlDZlNLWTFPVU5vaS1RZUhOaTM4aDN1NWFlNjdqeWNiV3R3T0U2OEJrSjNqbW1ZMWllVC1TRmt6ZWlxSFFlYWxTMF9BU0FZYnNVZENBbW5DODJzWUszS3RnVjJXaEZKLUl1VlFrYUxKTnJWVXc1SlBHdXdXS1VONA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON\u2019s Phase 3 OVATION 3 Trial in Advanced Ovarian Cancer Recommended to Continue by Independent Data Monitoring Committee", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPWmVuUS1aa1BtTXM1NndtSzhjTWNKLU1qN0prSERvVWZxU3RZTkl4Z1NXRHhpLU1OVkh5Q1NEVmMyeEFGWmc5WTJFU2F3T1ZUUHp1bktveGJ4MjRtOUN6dG1iXzd3T0NxazJLWm83YW9xOXRzMVh2UUMwWTNZZE5ZT2lxTzhmMG4wdWZ5cnVVN21zRGVjcHhhSV9aNXlnVUhUXzY4ZElvNjczVFV6OXZrT0FybzZ1UHV1M3BkdldBWF9kMHQ3alBoeDhDNDVNaXRsWmNkWU82Nm50QmZLQmVCWlo2dGpNbXJSV2dEYnNwQW5ISkpRdkJ6TA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON ovarian cancer trial stays on track after safety review", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPb1ZqLV9FUWFrRFBLXzJQSzV5RXk0N1c1QnRSbnNUWjRjenBmQkd3UXlhTEF4RF9wTWNVUTRhajJmeDBockd2eDdTN0xSZ1h3NVFlN3RUcS1fbDVrMGdrR05wUnhIZ3pfUHZpbTJKbWdMeXJJT3NQYkEtTjZSSkVXSk1Yb0RMV3pBdy1YWWZ1b0doZzVjSnpnNndtT3JaanlpeU9MTHE2enZlc0x3MUdTcnp0bjk4WjF0N0M0YVlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON to Present at the Life Sciences Investor Forum on June 25th", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/imunon-present-life-sciences-investor-201500924.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:15:00+00:00", "published_display": "22 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON CEO to take live questions June 25 at investor forum", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWVlDTDlJeWhFN3B1YkNiVFlfbmViM2xtZHcwcHFHZHZ1MDh6OVFSWWc1NTBjS29VbzhmeTBNUmtDTmctTmttVE0wb091OHhCcUZlOHQ5X0k5TzFjbFFxdm96cnlBOG9xSWhVTUNIQXIzWU9zV0pvcnlKVWc3U1RQUW5lZXM1TmpDaklGWmlFR0FYRHJxSGxTNHZFT3B3aWg1YnVmOWh1dUszVjVqZTFzWWxFbGFyQ1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)", "summary": "", "url": "https://finance.yahoo.com/m/0d6c8b3c-3e89-3260-8f6d-9a1b035ee5f7/imunon-secures-%2410-million.html", "source_name": "InvestorsHub", "published_at": "2026-06-04T14:32:14+00:00", "published_display": "04 Jun 2026 14:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON Announces Up to $10 Million Cash Financing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/imunon-announces-10-million-cash-120000292.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON raises $10M after ovarian cancer drug shows 14.7-month gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQWWNXQzJtZEV4bUtBWXlqMHM3bWNHSEMzX1lfdnlYVVR2MU41ajliRWYxQ1J1d25GU2ZYQjJFSF92aF8zX25nVmdkT3JqZVlwaVU0d1ZqOXlGWHB6ck43bndLMEtlZUVSX0hvSDhfWkwyVy11OFF5UHlKMF9RUGpMYUthcTNBdVg1OUpTYlBrR192eUs4ZG50Zg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon Secures $10 Million Financing From Streeterville Capital; Issues Preferred Stock and Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNYkh3S2lXS1M0MVhicXJmb3FJLXRydkhrUGMyTGJEcjR5M25uRmozLUdCQjk0cENYRFBLeWtNdWxTM2trNUhXeUtySmpldlRpUDY5LUtOeTg3aTFmYmgwQTM1a0V0cVprdEdOdUJjWUt3UXE0eGlyM0MzaW1vc0VjbDdvUUQ1NGdqMk44eHo2alo2UEl5NmsxdHQyTUtCbW9lSXNEc0ZtRDZDbV9ZSERZMXoyNzZyQXg1WUlzZk1Oa2lmcmpxZWVLbGxrTG5SNDJZOHNVcFp2ZFAtclNRWmMzaVduZmNpYXVOWkd6bDRn?oc=5", "source_name": "TradingView", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon IMNN Q4 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/77750952-a2fb-3f6a-b5a6-934811196618/imunon-imnn-q4-2025-earnings.html", "source_name": "Motley Fool", "published_at": "2026-06-01T15:47:00+00:00", "published_display": "01 Jun 2026 15:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "May 12 webcast to cover IMUNON's Q1 results, Phase 3 ovarian cancer update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZnprVjhXTjFrbEFSbWZOcndKd0ZMX2xfN3RYTlA5bVNXODVuek11U3Vob1phRlVPb3N3cFY1OWdLdGVubUY4LWF0aG1raWpOTGlqMTZOalBXSVgySDFaVXJhTVJXaE5uZXhzOFdZZ2dqSWFQR1JRTllTdGNKQlFmMWFIRzNONjh3bnZkdkc1YTVpMGNsX1ZGOUE5bklvaGJRa19jcF9EZkp2X3JWbkN0SjVzRzNzUERfaTlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON Reports 2025 Financial Results and Provides Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxPX0NuT0hFdXRLdS1HcGpTNFVldWlGSDVHUnp1a1NnRkdqUWlQM1pXUlNLYWY4VHExSHhoS2dkcGxtYnhBVFlBR1RtTG9UWGpKV0ZDbXprRHVxZktrM3N1S2R4SnFXc21YYkNWbGdTY3JLODB3eW0xQS1wVTJYRGpUaXhGc3Jxd2ZORTVOeTc5MnBlMjdyWFBpNzdRLWV4SEZ6NE1LQ1JNUnQ5MDBhZ3RJckRta3lhMjdabnBrZXlDTnZKcTEtc0RKWjZIdlFwM3JDa2xwQTdqdG02NV9zTk9VeThvUGdxWWNKQ3pDVTBlZGtTbG04dzdpUXkxZnF3czQzVVJUMno1NWE2SkRBUUc2NGwxY3JyV1FEQWw3dHdzVlNwZFZIWmc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON Reports Updated Phase 2 Data Showing Continued", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxPZEoyRG90cWxrNWw3QWJrYzBBR3hfc21JWU1QZUhqZ1BDRjlKVC1ic2luOEVrNTRQQzdEWF9LZ1JHVC1GZThQSTloUHYwZjhBXzB4NHczdWExbk53NXNOS1IwendMZlZoclFYNWh1TUZLdXdGVElHbDJIekM4a01mcXQ5NmVSdENEay1oMF9COTM5UmgzMldlUHlRM2l2eXJBT2pYTU0yblBhS0ZZR2hsZ2pOaThmaGNPclRhZ1prb1c5RjZzNUNrUDBmcnlXalctNmFuaEJFS1ZpMEt6V0gwUkl3eEpZVjBfUmtIVzNFLUZLZGk0bmpqMXczSlR2Ylp1bHpBVWpGdGV3bF9sdnBSYjFwOFFLOVYydnhleXcybkZEQUdBYWNldGR6bkZBTWRoTVpEUDJ0RFcyeGtvRU9vbjZDQjBtbGFxbGhOcTJiMTM1dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNSGxKSGtPZ1dmSV96MFdVbEc5U183M1NwSmhjcXZkM3BMNFYwUTBUTjVGc0w2ZkNhdDlDS2J6SzN2T1FrVXd2UEV3N0EtanBfSkY5VkI1ZlRxY1luaVhJYURMblN1QWh5SHF0WnNSY0NRU1kxWEs3S1ZlNEF2OUNvWl84eHljSUZXa3JaRkZKeTNwUWZIWVVjS1JLU2M4QWNrNFdkTnBzYWstWE1ubHlMSW9Xc3hxeHh5cEw0azZiZXZBbGt5amZZTWZqNWNadDFtczFqZFNfR0Fuc2Mzdml1QWlIc3lKcW1lcHozZ0V0dFgxcVotWW5XNVYxcnVYY28?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imunon (IMNN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBGVnRGYUhsYXhWM2kyb094eTUyX0c5eGZBLVY5ajF6M0NJMERFbkFCVDlFU2diWkdSUzBNS2JNLWhicVlTOTNHaGlQa2EzTVhOQ2JKTk9nemJZZw?oc=5", "source_name": "MarketBeat", "published_at": "2022-09-24T13:23:29+00:00", "published_display": "24 Sep 2022 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 56, "sentiment_summary": {"positive": 2, "negative": 8, "neutral": 46, "score": 48, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.65, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "liquidity", "label": "Balance sheet", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 2.02, "latest_week": "2026-07-10", "one_week_move": 5.8, "four_week_move": 0.0, "twelve_week_move": -34.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.704111, "market_dynamics_buy_signal": false, "relative_strength": -56.790962, "fair_value_gap": -80.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.404, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.8% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "TradingView", "count": 12}, {"label": "GlobeNewswire", "count": 6}, {"label": "Market source", "count": 5}, {"label": "Investing.com Nigeria", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Zacks Small Cap Research", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 16}, {"label": "Balance sheet", "count": 7}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.8% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR\u2019s David Bautz, PhD"}], "updated_at": "2026-07-16T13:29:54.887855+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}